All In Biotech

Free tool

FAERS Monitor: Lanreotide Acetate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215395 or its brand name (Lanreotide Acetate, Lanreotide Acetate). Reports on generic versions are filed under their own applications.

Reports

3,387

Serious

3,167

94% of reports

Hospitalization

1,126

Death reported

1,185

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,038
  • off label use943
  • diarrhoea596
  • fatigue454
  • abdominal pain347
  • nausea328
  • malignant neoplasm progression327
  • weight decreased281
  • malaise270
  • asthenia269
  • dizziness237
  • vomiting234
  • headache214
  • decreased appetite204
  • product dose omission issue194

Reports by year received

View as table
YearReports
20062
20091
20101
20111
20123
20133
20143
20151
20162
20176
201829
201941
202058
2021198
2022338
2023868
2024666
2025753
2026413

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,772 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal32719.917.95,857
abdominal painSignal3479.38.42,578
deathSignal1,0387.57.16,072
off label useSignal9436.76.34,754
weight decreasedSignal2816.35.61,251
diarrhoeaSignal5965.75.32,398
decreased appetiteSignal2045.54.8746
astheniaSignal2694.44.0727
product dose omission issueSignal1944.13.6458
malaiseSignal2703.83.4572
fatigueSignal4543.63.3892
vomitingSignal2343.12.7336
dizzinessSignal2373.02.6311
nauseaSignal3282.62.3326
headacheSignal2142.11.9129

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.